The new guidance offers improved clarity on disclosure in the prospectus and suitability for listing of biotech companies.

Since the implementation of the new listing regime for biotech companies under Chapter 18A of the Main Board Listing Rules (the Listing Rules) on April 30, 2018, The Stock Exchange of Hong Kong Limited (the Exchange) has offered more diversified choices for investors. Drawing from the Exchange's experience in the last two years and market feedback, the Exchange has recently released important and new guidance in relation to listing of biotech companies under Chapter 18A of the Listing Rules, which offer improved clarity on the relevant issues, including disclosure requirements and suitability for listing.